Syros Pharmaceuticals Shares Plummet Premarket
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed,
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
The Kia Syros is expected to debut sometime in the coming weeks. Its market launch is part of the “Kia 2.0 Strategy” for the ...
Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.
The upcoming Kia Syros will most likely be positioned between Sonet and Seltos, therefore, potentially creating a new segment ...
2d
Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...
TipRanks on MSN2d
Syros downgraded to Market Perform from Outperform at JMP SecuritiesJMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback